Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics

PURPOSE: Zinc metallochaperones (ZMCs) are a new class of anti-cancer drugs that reactivate zinc deficient mutant p53 by raising and buffering intracellular zinc levels sufficiently to restore zinc binding. In vitro pharmacodynamics of ZMCs indicate that p53 mutant activity is ON by 4–6 hours and is...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yu, Xin, Kogan, Samuel, Chen, Ying, Tsang, Ashley T., Withers, Tracy, Lin, Hongxia, Gilleran, John, Buckley, Brian, Moore, Dirk, Bertino, Joseph, Chan, Chang, Kimball, S. David, Loh, Stewart N., Carpizo, Darren R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139040/
https://ncbi.nlm.nih.gov/pubmed/29914895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0822
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados